# A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants

Study · id `cardio:ct-nct07876492` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07876492](<https://clinicaltrials.gov/study/NCT07876492>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07876492

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 6106 participants.

## Technical summary

Registry record NCT07876492. Randomized; quadruple masking; primary purpose prevention. Start 2026-11-20 (anticipated); primary completion 2029-12-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 6106 participants (planned count; ClinicalTrials.gov record NCT07876492, source copy `cardio:ctgov-nct07876492-2026-10-15`, retrieved 2026-10-26)
- Planned start: 2026-11-20 (anticipated) (ClinicalTrials.gov record NCT07876492, source copy `cardio:ctgov-nct07876492-2026-10-15`, retrieved 2026-10-26)
- Primary completion: 2029-12-15 (anticipated) (ClinicalTrials.gov record NCT07876492, source copy `cardio:ctgov-nct07876492-2026-10-15`, retrieved 2026-10-26)
- Completion: 2029-12-15 (anticipated) (ClinicalTrials.gov record NCT07876492, source copy `cardio:ctgov-nct07876492-2026-10-15`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07876492-2026-10-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
- Acronym: ROXI-DAISEN
- Condition: Secondary Stroke
- Intervention (Drug): Cenvacibart
- Intervention (Drug): Placebo
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: c60b77dcee6b79c0471dee07caf415317e4de16dc9f1cb01409e248aea370913
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
